Novartis receives positive CHMP opinion for first-line use of Zykadia ® in ALK-positive advanced non-small cell lung cancer (NSCLC)

Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of expanding the use of Zykadia® (ceritinib) to include the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news